Literature DB >> 9213251

Radiofrequency capacitive hyperthermia for unresectable hepatic cancers.

K Yamamoto1, Y Tanaka.   

Abstract

Radiofrequency capacitive hyperthermia combined with intra-arterial chemotherapy or chemoembolization was performed in 45 patients with unresectable hepatic cancer. Intratumor temperature was measured in 26 (57.8%) of the 45 patients. The overall mean maximum core temperature (Tmax) was 41.3 +/- 0.3 degrees C (mean +/- SE), and the Tmax was > or = 42 degrees C in nine tumors (34.6%). The tumor temperature rise was related to the power applied, embolization with degradable starch microspheres, and obstruction of the portal vein. The overall response rate was 31.1% (14/45). The response rate was 55.6% when Tmax was > or = 42 degrees C; although this was higher than the response rate of 11.8% achieved with Tmax < 42 degrees C, the difference was not significant. There were no serious adverse effects of hyperthermia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9213251     DOI: 10.1007/bf02934494

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  15 in total

1.  EFFECTS OF HYPOXIA AND HYPERTHERMIA ON HEPATIC TISSUE OF THE DOG.

Authors:  W A REED; R T MANNING; L T HOPKINS
Journal:  Am J Physiol       Date:  1964-06

2.  [Antitumor effect and indication of chemoembolization using degradable starch microspheres and regional hyperthermia in patients with hepatocellular carcinoma].

Authors:  T Yoshikawa; H Oyamada; H Ichikawa; Y Naito; S Ueda; K Tainaka; K Itani; O Seto; S Sugino; M Kondo
Journal:  Nihon Gan Chiryo Gakkai Shi       Date:  1989-04-20

3.  Guide to the use of hyperthermic equipment. 1. Capacitively-coupled heating.

Authors:  M Kikuchi; Y Amemiya; S Egawa; Y Onoyama; H Kato; H Kanai; Y Saito; I Tsukiyama; M Hiraoka; S Mizushina
Journal:  Int J Hyperthermia       Date:  1993 Mar-Apr       Impact factor: 3.914

4.  Hyperthermic isolation-perfusion in vivo of the canine liver.

Authors:  J L Skibba; R E Condon
Journal:  Cancer       Date:  1983-04-01       Impact factor: 6.860

5.  Relationships among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas.

Authors:  K A Leopold; M Dewhirst; T Samulski; J Harrelson; J A Tucker; S L George; R K Dodge; W Grant; S Clegg; L R Prosnitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

6.  Radiofrequency thermotherapy for malignant liver tumors.

Authors:  Y Nagata; M Hiraoka; K Akuta; M Abe; M Takahashi; S Jo; Y Nishimura; S Masunaga; M Fukuda; H Imura
Journal:  Cancer       Date:  1990-04-15       Impact factor: 6.860

7.  Hyperthermochemotherapeutic in vivo isolated perfusion of the rat liver.

Authors:  M Miyazaki; L Makowka; R E Falk; W Falk; D Venturi; U Ambus; J A Falk
Journal:  Cancer       Date:  1983-04-01       Impact factor: 6.860

8.  Thermal sensitivity to single and double heat treatments in normal canine liver.

Authors:  S D Prionas; M A Taylor; L F Fajardo; N I Kelly; T S Nelsen; G M Hahn
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

9.  Analysis of prognostic variables in hyperthermia treatment of 161 patients.

Authors:  J R Oleson; D A Sim; M R Manning
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-12       Impact factor: 7.038

10.  Retrospective analysis of the response of tumours in patients treated with a combination of radiotherapy and hyperthermia.

Authors:  J Van der Zee; W L Van Putten; A P Van den Berg; G C Van Rhoon; J L Hooley; M P Broekmeyer-Reurink; H S Reinhold
Journal:  Int J Hyperthermia       Date:  1986 Oct-Dec       Impact factor: 3.914

View more
  1 in total

1.  Non-Invasive Radiofrequency Field Treatment to Produce Hepatic Hyperthermia: Efficacy and Safety in Swine.

Authors:  Jason C Ho; Lam Nguyen; Justin J Law; Matthew J Ware; V Keshishian; N C Lara; Trac Nguyen; Steven A Curley; Stuart J Corr
Journal:  IEEE J Transl Eng Health Med       Date:  2017-04-03       Impact factor: 3.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.